Parkinson's disease: Braak" to the future."

Blesa J.

Mov Disord. 2013 Aug;28(9):1209. doi: 10.1002/mds.25498. No abstract available.

Lysosomal enzyme defects and Parkinson disease.

Sharma N.

Neurology. 2013 Apr 23;80(17):1544-5. doi: 10.1212/WNL.0b013e31828f1958. No abstract available.

The role of autophagy in Parkinson's disease: rotenone-based modeling.

Xiong N, Xiong J, Jia M, Liu L, Zhang X, Chen Z, Huang J, Zhang Z, Hou L, Luo Z, Ghoorah D, Lin Z, Wang T.

Behav Brain Funct. 2013 Mar 15;9:13. doi: 10.1186/1744-9081-9-13.

Mild cognitive impairment in Parkinson's disease: millstone or milestone?

Burn DJ, Barker RA.

Pract Neurol. 2013 Apr;13(2):68-9. doi: 10.1136/practneurol-2013-000539. No abstract available.

A systematic review of impulse control disorders in Parkinson's disease.

Callesen MB, Scheel-Krüger J, Kringelbach ML, Møller A.

J Parkinsons Dis. 2013;3(2):105-38. doi: 10.3233/JPD-120165. Review.

Psychiatric factors related to sexual functioning in patients with Parkinson's disease.

Kotková P, Weiss P.

Clin Neurol Neurosurg. 2013 Apr;115(4):419-24. doi: 10.1016/j.clineuro.2012.06.020.

Exercising improves walking speed for people with Parkinson's.

[No authors listed]

Harv Mens Health Watch. 2013 Mar;17(8):8. No abstract available.

Cardiac sympathetic denervation in Parkinson's disease patients with SWEDDs.

Jang W, Kim JS, Cho JW, Kim YH, Kim JY, Choi YY, Kim HT.

Neurol Sci. 2013 Aug;34(8):1375-82. doi: 10.1007/s10072-012-1244-1.

Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease.

Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N.

J Mol Neurosci. 2013 Nov;51(3):863-70. doi: 10.1007/s12031-013-0075-8.

Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W; Pramipexole ER Studies Group..

Eur J Neurol. 2013 Jan;20(1):50-6. doi: 10.1111/j.1468-1331.2012.03712.x.

High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson's disease.

Maruo T, Hosomi K, Shimokawa T, Kishima H, Oshino S, Morris S, Kageyama Y, Yokoe M, Yoshimine T, Saitoh Y.

Brain Stimul. 2013 Nov;6(6):884-91. doi: 10.1016/j.brs.2013.05.002.

Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.

Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM.

Parkinsonism Relat Disord. 2013 Feb;19(2):218-21. doi: 10.1016/j.parkreldis.2012.10.008.

Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson's patients leukocytes.

Soreq L, Bergman H, Israel Z, Soreq H.

BMC Genomics. 2013 Jul 16;14:478. doi: 10.1186/1471-2164-14-478.

[Depression in Parkinson's disease].

Kitamura S, Nagayama H.

Seishin Shinkeigaku Zasshi. 2013;115(11):1135-41. Review. Japanese.

The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients.

Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P.

Funct Neurol. 2013 Jan-Mar;28(1):13-7.